WELVASTA-F contains Fenofibrate 160 mg + Rosuvastatin 10 mg, combining complementary lipid-lowering mechanisms for selected patients with mixed dyslipidaemia. A strategically useful PCD Cardiac-Diabetic product.
To address mixed dyslipidaemia involving elevated LDL and triglycerides.
Yes.
Use under physician supervision. Monitor lipid profile and liver function as clinically appropriate. Report unexplained muscle pain or weakness promptly.
Muscle pain, abdominal discomfort, nausea, headache and liver enzyme elevations may occur. Combination therapy requires attention to muscle-related adverse effects.
WELVASTA-F: Rosuvastatin reduces LDL cholesterol through HMG-CoA reductase inhibition, while Fenofibrate activates PPAR-α to improve triglyceride metabolism and lipid handling.
